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Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells due
to SOCS-3 Epigenetic Silencing
Hajime Isomoto1, Justin L. Mott1, Shogo Kobayashi1, Nathan W. Werneburg1, Steve F.
Bronk1, Serge Haan2, and Gregory J. Gores1
1 Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, United States
2 Institut fur Biochemie, Rheinisch-Westfalische Technische Hochschule Aachen, Pauwelsstrasse 30,
D-52074 Aachen, Germany
Abstract
Background and aims—IL-6 mediated STAT-3 phosphorylation (activation) is aberrantly
sustained in cholangiocarcinoma cells resulting in enhanced Mcl-1 expression and resistance to
apoptosis. Because SOCS-3 controls the IL-6/STAT-3 signaling pathway by a classic feedback loop,
the aims of this study were to examine SOCS-3 regulation in human cholangiocarcinoma.
Methods—SOCS-3 expression was assessed in human cholangiocarcinoma tissue and the Mz-
ChA-1 and CCLP1 human cholangiocarcinoma cell lines.
Results—An inverse correlation was observed between phospho-STAT-3 and SOCS-3 protein
expression in cholangiocarcinoma. In those cancers failing to express SOCS-3, extensive methylation
of the SOCS-3 promoter was demonstrated in tumor but not in paired non-tumor tissue. Likewise,
methylation of the socs-3 promoter was also identified in two cholangiocarcinoma cell lines.
Treatment with a demethylating agent, 5-aza-2 -deoxycytidine (DAC), restored IL-6 induction of
SOCS-3, terminated the phospho-STAT-3 response, and reduced cellular levels of Mcl-1. Enforced
expression of SOCS-3 also reduced IL-6 induction of phospho-STAT-3 and Mcl-1. Either DAC
treatment or enforced SOCS-3 expression sensitized the cells to TRAIL-mediated apoptosis.
Conclusion—SOCS-3 epigenetic silencing is responsible for sustained IL-6/STAT-3 signaling and
enhanced Mcl-1 expression in cholangiocarcinoma.
Keywords
apoptosis; 5-aza-2 -deoxycytidine; CpG islands; methylation-specific PCR; STAT-3; TRAIL
Cholangiocarcinoma is an aggressive neoplasm with differentiated features of bile duct
epithelia, and current concepts suggest that this cancer arises from bile duct epithelial cells.1
Chronic bile duct inflammation is an established risk factor for the development of
cholangiocarcinoma.2–4 As chronic inflammation is being increasingly recognized as an
integral component of many cancers including several gastrointestinal malignancies,1, 4–8
cholangiocarcinoma is a model disease to investigate the relationship between chronic
inflammation and the initiation and progression of cancers. Insight into how inflammation
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promotes this malignancy may also provide therapeutic strategies for the treatment of this
otherwise devastating disease.9
Cytokines produced in the inflammatory environment have an important role in cancer
pathogenesis.5–7, 10–12 The cytokine interleukin 6 (IL-6) has been demonstrated to have an
integral role in cholangiocarcinoma biology and other cancers as a growth and survival factor.
11, 13–19 For example, we have recently demonstrated that IL-6 induces expression of the
potent anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1) in cholangiocarcinoma cells via
phosphorylation of a pivotal transcription factor, signal transducers and activators of
transcription 3 (STAT-3) phosphorylation.18 Mcl-1 expression provides this cancer resistance
to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).20 Inhibition of IL-6
induced expression of Mcl-1 restores sensitivity to TRAIL19; an observation of therapeutic
relevance.21, 22 Our prior studies suggested IL-6 signaling was aberrant in
cholangiocarcinoma cells with prolonged and sustained STAT-3 phosphorylation; a
mechanism likely accounting for upregulation of Mcl-1 expression by these cancers.18 The
mechanisms responsible for this atypical IL-6 signaling response are unclear but of
pathophysiological importance.
Under physiologic conditions, IL-6 via a Janus kinase (JAK)/STAT-3 pathway induces
expression of suppressor of cytokine signaling 3 (SOCS-3).23–27 This protein has a high
affinity for tyrosine 759 of the plasma membrane protein, gp130, an integral member of the
IL-6 signaling complex.23, 25, 27, 28 By binding to this residue, SOCS-3 is able to inhibit
IL-6 signaling thereby turning it off in a classic feed back loop.23–27 Silencing of SOCS-3 is
a potential mechanism explaining the sustained IL-6 induced STAT-3 phosphorylation
observed in cholangiocarcinoma cell lines.18 Recent reports suggest SOCS-3 may be silenced
by epigenetic phenomenon in human cancers, namely methylation of CpG islands [(DNA
regions greater than 500 bp with a G+C content equal to or greater than 55% of total nucleotides
and a ratio of observed to expected CpG nucleotides >0.6)29] within the SOCS-3 promoter.
30–32 Methylation of cytosine residues within promoter CpG islands is a well-established
epigenetic process causing gene silencing.33, 34 Thus, CpG island methylation is an attractive
mechanism explaining sustained IL-6 signaling in human cholangiocarcinoma.
The overall objective of this study was to examine SOCS-3 expression in human
cholangiocarcinoma tissue and cell lines. To address this objective we formulated several
questions as follows: i) Is there an inverse relationship between phosphorylated STAT-3 and
SOCS-3 expression in human cholangiocarcinoma tissue?; ii) Is SOCS-3 silencing in human
cholangiocarcinoma tissue and cell lines associated with CpG island methylation of its
promoter?; iii) Does a demethylating agent restore SOCS-3 expression in human
cholangiocarcinoma cells?; and iv) Does SOCS-3 expression inhibit IL-6 mediated STAT-3
phosphorylation, reduce cellular Mcl-1 protein levels, and restore sensitivity of human
cholangiocarcinoma cells to TRAIL-mediated cytotoxicity? The results indicate that SOCS-3
is commonly silenced in human cholangiocarcinoma by epigenetic methylation of its promoter.
The demethylating agent restores SOCS-3 expression, reduces Mcl-1 protein expression and
augments cellular sensitivity to TRAIL. The data suggest epigenetic therapy of this cancer may
be a useful therapeutic strategy.
Materials and Methods
Human Liver Tissue
After approval by the Mayo Clinic Institutional Review Board, immunohistochemical analysis
was performed on 26 archived surgically resected liver specimens of patients with intrahepatic
cholangiocarcinoma.
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The 5- m thick tissue sections of surgically resected cholangiocarcinoma, were deparaffinized
in xylene, hydrated with graded ethanol and distilled water. Immunohistochemical staining
was performed employing the DakoCytomation Envision+ System-HRP (DAB)
(DakoCytomation, Carpinteria, CA) as described previously.19 The following steps were
performed at room temperature unless otherwise specified. Briefly, after inhibition of
endogenous peroxidase activity with blocking solution containing 0.03% H2O2 supplied by
the kit for 5 min, the sections were incubated in blocking buffer (5% normal goat serum in
phosphate buffer saline containing 0.05% Tween-20 [PBST]) for 30 min, and incubated
overnight with rabbit phospho-STAT-3 (Tyr 705) polyclonal antibody diluted 1:200 with
blocking buffer, or rabbit anti-SOCS-3 polyclonal antibody diluted 1:200 with blocking buffer
at 4°C overnight. For negative control, the primary antibody was replaced with a normal rabbit
immunoglobulin.
After incubation with the primary antisera, the sections were washed in PBS-T and incubated
with peroxidase-labeled polymer conjugated to goat anti-rabbit immunoglobulins supplied by
the kit for 30 min. The sections were then washed again with PBS-T and stained with 3,3 -
diaminobenzidine chromogen solution containing hydrogen peroxidase supplied by the kit for
5 min, washed in distilled water for 1 min, counterstained with hematoxylin for 20 seconds,
and washed again in distilled water for 3 min. Following dehydration, the tissue slides were
soaked in xylene, mounted and examined by light microscopy. To evaluate positive reactivity
of the antibodies, the percentage of the cells which contained nuclear (phospho-STAT-3)
immunoreactivity or cytoplasmic (SOCS-3) immunoreactivity were quantitated. Only cells
with immunoreactivity above background were considered positive. A minimum of 500 cells
per specimen were examined and quantitated.
Laser capture microdissection and DNA isolation
The 5-mm paraffin-embedded sections were deparaffinized by incubation in a xylene (3×5
min), followed by rehydration through a series of 100, 95 and 75% ethanol (1 min each). After
rinsing in sterile distilled water, the sections were stained using Histogene refill kit (Arcturus
Engineering, Mountain View, CA), dehydrated in 75, 95 and 100% ethanol (1 min each),
followed by xylene (2×5 min). Once air-dried, the slides were used for laser capture
microdissection (LCM) employing the AutoPixcel LCM system (Arcturus Engineering).
Target cell populations from the neoplastic and normal surrounding tissues (bile duct epithelial
cells and hepatocytes) distant (at least 1cm) from neoplastic lesions were procured. The
captured cells were incubated in proteinase K buffer (Arctrus Engineering) at 65°C overnight
and genomic DNA was isolated from the captured cells using the DNA PicoPure isolation kit
(Arcturus Engineering).
Methylation-specific PCR
Genomic DNA was subjected to bisulfite modification as described by Herman et al.35 Briefly,
2 g of genomic DNA was denatured with 0.2 M NaOH at 37°C for 10 min and treated with
10 mM hydroquinone and 3M sodium bisulfite (pH 5.0) at 50°C for 16h. The modified DNA
was purified using the Wizard DNA purification resin (Promega, Madison, WI), treated with
0.3 M NaOH, precipitated with ethanol and resuspended in 20 L water. Two- L aliquots were
used as templates for methylation-specific PCR (MSP). MSP was performed under conditions
described previously32 using either a methylation- or unmethylation-specific primer set.
Sequences of the methylation-specific SOCS-3 primer pairs designed to amplify nucleotides
-525 to -384 of the SOCS-3 promoter region (the start codon ATG is defined as +1) and the
unmethylation-specific primer ones designed to amplify nucleotides -528 to -382 were shown
in Table 1. The PCR products were electrophoresed on a 2% agarose gel, stained with ethidium
bromide and visualized under ultraviolet illumination. Human male genomic DNA treated with
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methyltransferase (Chemicon International, Temecula, CA) was used as a methylation-positive
control.
Bisulfite sequencing
Bisulfite-treated genomic DNA was amplified using primers to amplify -704 to -186 of the
SOCS-3 promoter region (Table 1), adopting the protocols described previously.31 The PCR
products were cloned into the pCR II vector in accordance with manufacturer’s instruction
employing the TOPO-TA cloning kit (Invitrogen, Carsbad, CA). Plasmid DNA purified from
5 randomly picked clones using the plasmid miniprep kit (Bio-Rad Laboratories, Hercules,
CA) were obtained and prepared for automated DNA sequencing analysis. The reaction
conditions were as follows: 96°C for 10 sec, 50°C for 5 sec, 60 for 4 min for 25 cycles. DNA
was sequenced using dye terminator technology and a ABI 3730xl sequencer (Applied
Biosystems, Foster City, CA).
Cell lines and culture
The human cholangiocarcinoma cell line, Mz-ChA-136 was cultured in Delbecco’s modified
Eagles’s medium (DMEM) supplemented with 10% fetal bovine serum, penicillin G (100,000
U/L), streptomycin (100 mg/L), and gentamycin (100 mg/L). The CCLP137 cell line, a
malignant human cholangiocarcinoma cell line (kindly provided by A.J. Demetris, University
of Pittsburgh, PA) was cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 50 g/ml gentamycin, and 10 mM HEPES. H69 cells, immortalized human non-
malignant cholangiocytes, were kindly provided by Dr. Doug Jefferson (Tufts University,
Boston, MA) and cultured as described previously.38
Immunoblot analysis
The cells were directly lysed for 30 min on ice with lysis buffer [50 mM Tris-HCl (pH 7.4),
1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF,
1 g/mL aprotinin, 1 g/mL leupeptin, 1 g/mL pepstatin, 1 mM Na3VO4 and 1 mM NaF]. After
centrifugation at 13,000 g for 15 min, protein concentrations were measured using Bradford’s
reagent (Bio-Rad), and protein was denatured by boiling for 10 min, Protein (25 g) was loaded
onto sodium dodecyl sulfate-polyacrylamide gels for electrophoresis, and then transferred onto
nitrocellulose membranes. After blocking with 5% milk in TBST (137 mM NaCl, 25 mM Tris
and 1 mM disodium ethylenediaminotetraacetate containing 0.1% Tween-20), the membranes
were incubated with primary antibodies at 4°C overnight. After washing with TBST three times
(each for 10 min), the membranes were incubated with their corresponding horseradish
peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 hr. After
washing with TBST three times (each for 10 min), bound antibodies were visualized using
enhanced chemiluminescent substrates (ECL; Amersham, Arlington Heights, IL).
DNA sequencing
Genomic DNA was extracted from the cell line using the Wizard SV genomic DNA purification
system (Promega), and amplified by PCR using the primers designed to cover the entire
socs-3 gene on chromosome 17q25.3 (GI: 37542591) consisting of 2 exons, 1 intron and 5 -
and 3 -franking regions (Table 1). PCR products were electrophoresed on a 1% agarose gel,
stained with ethidium bromide, visualized under ultraviolet illumination and purified using a
gel extraction kit (Qiagen, Valencia, CA). The purified DNA was sequenced as described
above.
Electrophoretic Mobility Shift Assay
Nuclear extract were prepared from confluent cells as follows. Hypotonic swelling and lysis
were carried out in the culture dish in lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1
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mM EDTA, 0.4% Nonidet P-40, complete protease inhibitors (Roche Diagnostics, Indianna
IN), and 0.1 mM DTT), followed immediately by scraping and collection on ice. Nuclei were
then pelleted by centrifugation, and resuspended in extraction buffer (20 mM HEPES, 400 mM
sodium chloride, 1 mM EDTA, 10% glycerol, complete protease inhibitors, and 0.1 mM DTT).
Protein concentration was determined by the Bradford method, and extracts frozen at 80°C
until use.
Binding reactions containing 2.5 micrograms of nuclear extract protein were incubated at room
temperature for 30 minutes with 0.5 L of double-stranded STAT-3 oligo (5  GAT CCT TCT
GGG AAT TCC TAG ATC; consensus sequence underlined) which was labeled with the
infrared fluorophore, IRDye700 (Li-cor Biosciences, Lincoln NE). The binding reaction was
performed in 10 L final volume, containing 10 mM Tris (pH 7.5), 50 mM KCl, 5 mM
magnesium chloride, 1 g poly(dI-dC), 0.25% Tween-20, 0.05% Nonidet P-40, and 3.5 mM
DTT. Cold competitor was the same double-stranded sequence without label (Mayo DNA
Synthesis Core Facility, Rochester MN). Samples were separated on 5% polyacrylamide gels
in 0.25X Tris-Borate EDTA buffer (32.5 mM Tris, pH 8.3, 11.25 mM Boric Acid, 0.625 mM
EDTA). Imaging was done in the gel cassette on the Odyssey Infrared Imaging System (Li-
cor Biosciences, Lincoln NE). Control experiments (not shown) confirmed that the binding of
the probe was sequence specific as 200-fold molar excess of unlabeled oligo sucessfully
competed the band away.
Real-time polymerase chain reaction
Total RNA was extracted from the cells using the Trizol Reagent (Invitrogen, Carlsbad, CA),
and was reverse transcribed into cDNA with Moloney leukemia virus reverse transcriptase and
random primers (both from Invitrogen). Quantification of the cDNA template was performed
with real-time PCR (LightCycler; Roche Molecular Biochemicals, Mannheim, Germany)
using SYBR green (Invitrogen) as a fluorophore. PCR primers for human SOCS-3 were listed
in Table 1. For an internal control, primers for 18S ribosomal RNA (rRNA) were purchased
from Ambion (Austin, TX). After electrophoresis in 2% agarose gel, each expected base pair
PCR product was cut out and eluted into Tris-HCl using the gel extraction kit (Qiagen). The
concentrations of extracted PCR products (copies/ L) were measured using a
spectrophotometer at 260 nm and used to generate standard curves. The inverse linear
relationship between copy and cycle numbers was then determined. Each resulting standard
curve was then used to calculate the copy number/ L in experimental samples. The relative
mRNA expression levels were expressed as a ratio of SOCS-3/18S rRNA (copies/ L) per each
sample. All PCR conditions and primers were optimized to produce a single product of the
correct bp size expected.
Plasmid transfection
Mz-ChA-1 cells were transfected with 1 mL of OptiMEM-1 medium (GIBCO-BRL,
Gaithersburg, MD) containing 6 L of Plus reagent supplied with Lipofectamine Plus
(Invitrogen), 5 g of human SOCS-3 cDNA subcloned into pcDNA3 vector (Invitrogen) by
the use of the BamHI and EcoRI restriction sites (pcDNA3-hSOCS-3)39 and 6 L of the
Lipofectamine reagent (Invitrogen), following the manufacturer’s instructions.
SOCS-3 small interfering RNA treatment
Small interfering RNA (siRNA) complementary to the SOCS-3 gene was designed using
custom SMARTPools from Dharmacon (Lafayette, CO).40 H69 cells in 6-well culture plates
were transfected with in 1.0 mL OptiMEM-1 medium containing 100 nM SOCS-3 siRNA and
6 L siPORT Lipid (Ambion, Austin, TX).
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After incubation in the presence or absence of 5-aza-2 -deoxycytidine (DAC) for 96 hr, the
cells were treated with 2 ng/mL of tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) for 12 hr. Apoptosis was quantitated by assessing the characteristic nuclear changes
of apoptosis (i.e., chromatin condensation and nuclear fragmentation) using fluorescence
microscopy (Eclipse TE200, Nikon Instruments, Melvile, NY) after DAPI staining at a
concentration of 10 g/mL for 15 min, as previously described.20 Caspase 3/7 activity in cell
cultures was measured using the Apo-ONE homogeneous caspase-3/7 assay (Promega)
following the manufacturer’s instructions.
Measurement of TRAIL secretion
Mz-ChA-1 cells were additionally incubated for 24 hr in DMEM medium alone following
treatment with DAC or vehicle for 96 hr. Supernatants were collected and centrifuged to
remove particulate debris. Levels of TRAIL in the supernatants were determined by an enzyme-
linked immunosorbent assay (ELISA) using a commercially available kit (R&D Systems,
Minneapolis, MN). Cells lysates were prepared from the cells and their protein contents were
measured by the Bradford’s method as described above.
Materials
Recombinant human IL-6 and TRAIL were obtained from R&D Systems. The following
primary or secondary antibodies were used: polyclonal rabbit anti-c-inhibitor of apoptosis
protein 1 (c-IAP-1), anti-c-IAP-2, anti-Mcl-1, anti-survivin, and anti-STAT-3, and polyclonal
goat anti- -actin and anti-SOCS-3 antisera were from Santa Cruz Biotechnology (Santa Cruz,
CA); monoclonal mouse anti-TRAIL and anti-TRAIL receptor 1 (TRAIL-R1), polyclonal goat
anti-TRAIL-R2 and anti-Fas-associated death domain (FADD) antisera were from Alexis (San
Diego, CA); polyclonal rabbit anti-Bcl-2 antibody was from BD Biosciences (San Jose, CA);
monoclonal mouse anti-Bcl-XL was from Exalpha Biologicals (Maynard, MA); polyclonal
rabbit anti-phosphospecific STAT-3 at Tyr705 antibody was from Cell Signaling Technology
(Danvers, MA); HRP-conjugated anti-goat, -rabbit and –mouse immunoglobulins were from
Biosource International (Camarillo, CA). DAPI, the demethylation agent, DAC and a histone
deacetylase inhibitor, trichostatin A (TSA) were purchased from Sigma Chemical (St Louis,
MO).
Statistical analysis
All data represent at least three independent experiments and are expressed as the mean
±standard error (SE). Statistical analysis was performed using a two-tailed Student’s t test or
chi-square test. A p value of less than 0.05 was accepted as statistically significant.
RESULTS
Is there an inverse relationship between phospho-STAT-3 and SOCS-3 protein expression
in human cholangiocarcinoma specimens?
Tyr705 phospho-STAT-3 was identified in 16 of 26 human cholangiocarcinoma specimens by
immunohistochemistry (Figure 1 A); the immunoreactivity was identified in the nucleus of the
malignant cells consistent with the transcription factor function of this phosphorylated protein.
In these specimens with phospho-STAT-3 nuclear immunoreactivity, SOCS-3
immunoreactivity was seen in less than a third of the cells. In contrast, phospho-STAT-3
immunoreactivity was intermediate (n=7) or rare (n=3) in the other 10 specimens and in these
cancers, SOCS-3 immunoreactivity was readily observed in 46–62% of cells (Figure 1A and
1B). Thus, in this limited number of human cholangiocarcinoma specimens, there was an
inverse relationship between Tyr 705 phospho-STAT-3 and SOCS-3 immunoreactivity.
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Is SOCS-3 mutationally inactivated in cholangiocarcinoma specimens?
Given the propensity for tumors to accumulate mutations, we tested whether the SOCS-3 gene
was mutated in genomic DNA recovered from laser-capture microdissected (LCM) samples.
There were no identified mutations within the entire coding sequence, or in the immediate 5
and 3  flanking regions.
Does SOCS-3 CpG island promoter methylation occur in human cholangiocarcinoma?
The SOCS-3 gene sequence appeared intact, so we considered the role of epigenetic silencing
of SOCS-3. Genomic DNA was extracted from paired tumor and non-tumor tissue procured
by LCM. The cell-type specific genomic DNA was subjected to methylation specific PCR of
the socs-3 promoter region, nucletotides -525 to -384. In 7 of the 8 (88%) SOCS-3 negative
cancers analyzed, a methylated PCR product was identified (Figure 1C). In contrast, no
methylated PCR product was observed in the SOCS-3-expressing cancers (Figure 1C). The
methylated PCR product from the SOCS-3-negative tumors was cancer specific as only
unmethylated PCR products were observed from paired normal bile duct tissue and hepatocytes
(Figure 1D).
Furthermore, a total of 44 CpG sites located between nucleotides -678 and -216 of the
socs-3 promoter were examined by bisulfite sequencing. Dense cytosine methylation was
observed in the CpG islands of the socs-3 promoter procured from the 7 SOCS-3-negative
cancers with the methylated product by MSP. A methylation map of CpG islands from a
representative tumor is depicted in Figure 1E. Only sporadic cytosine methylation was
identified in genomic DNA obtained form SOCS-3-positive cancers (Figure 1E). Cytosine
methylation was rarely observed in non-tumorous bile duct epithelial cells or hepatocytes
demonstrating the cytosine methylation of CpG islands was tumor specific when identified
(Figure 1E). These data demonstrate the presence of socs-3 promoter CpG island
hypermethylation in human cholangiocarcinoma specimens.
Do Mz-ChA-1 cells retain the SOCS-3 promoter methylation pattern observed in a subset of
human cholangiocarcinomas?
A cell line was needed to ascertain the functional significance of CpG islands methylation
within the socs-3 promoter. Mz-ChA-1 cells were selected as they are a representative well-
characterized human cholangiocarcinoma cell line.36 IL-6 failed to induce SOCS-3 expression
either at the mRNA or protein level (Figure 2A and B), and, furthermore, IL-6 stimulation
resulted in sustained STAT-3 Tyr 705 phosphorylation in these cells (Figure 2A). Consistent
with their SOCS-3 negative but sustained phospho-STAT-3 response to IL-6, Mz-ChA-1 cells
displayed socs-3 promoter methylation of CpG islands (Figure 3A and B). Finally, the SOCS-3
gene was sequenced in these cells and no mutations were identified.
In contrast, H69 cells, a transformed nonmalignant human cholangiocyte cell line, responded
to IL-6 with transient STAT-3 Tyr 705 phosphorylation and robust SOCS-3 induction (Figure
2A and B); the normal predicted response to IL-6 signaling.18, 23, 41 Only sporadic and
minimal socs-3 promoter methylation was observed in the H69 cells (Figure 3A and B).
Collectively, these data demonstrate that Mz-ChA-1 cells retain the socs-3 promoter
methylation pattern observed in many human cholangiocarcinomas.
Is socs-3 promoter methylation responsible for SOCS-3 silencing
To determine whether socs-3 promoter hypermethylation is responsible for socs-3 gene
silencing following IL-6 stimulation, the effects of DAC, a demethylating agent, were
examined. Treatment with DAC restored the expression of SOCS-3 protein (Figure 4A) and
significantly increased the relative mRNA levels in Mz-ChA-1 cells in a dose-dependent
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manner following IL-6 treatment (Figure 4B). On the other hand, addition of a histone
deacetylases inhibitor, TSA, did not substantially augment the effect of DAC (Figure 4A). To
confirm that the observations with DAC were due to demethylation of the socs-3 promoter,
methylation specific PCR was performed. Indeed, DAC treatment converted the methylated
PCR product to one which was unmethylated (Figure 4C). These observations indicate that the
observed socs-3 promoter methylation in Mz-ChA-1 cells was sufficient to silence expression
of this gene.
Is epigenetic silencing of socs-3 responsible for sustained Tyr 705 phosphorylation of
STAT-3?
To examine the relationship between SOCS-3 epigenetic silencing and the sustained phopho-
STAT-3, Mz-ChA-1 cells were treated with DAC in the presence and absence of IL-6 (Figure
5A). DAC associated re-expression of SOCS-3 decreased cellular levels of phosphorylated
STAT-3 in response to IL-6 and resulted in rapid termination of the sustained IL-6/STAT-3
response observed in the absence of DAC (Figure 5A). Forced expression of SOCS-3 by
plasmid transfection also resulted in a rapid termination of the IL-6-initiated STAT-3 Tyr 705
phosphorylation (Figure 5B). Conversely, siRNA targeted silencing of SOCS-3 in the H69
cells enhanced STAT-3 Tyr 705 phosphorylation following exposure to IL-6 (Figure 5C).
These observations implicate epigenetic silencing of SOCS-3 as a mechanism responsible for
the sustained IL-6-mediated STAT-3 response in cholangiocarcinoma cells.
Is the SOCS-3 promotor epigenetically silenced in CCLP1 cells?
To confirm that the results above were not cell-line specific, we examined the malignant
cholangiocarcinoma cell line CCLP1 for SOCS-3 promoter methylation. CCLP1 cells indeed
exhibit SOCS-3 silencing, similar to Mz-ChA-1 cells, as well as human tumor tissue.
Specifically, the SOCS-3 promoter was methylated in CCLP1 cells, determined by
methylation-specific PCR, and methylation was reversible with DAC treatment (Figure 6A).
Further, SOCS-3 expression was not induced by IL-6 treatment unless the cells were pre-treated
with DAC (Figure 6B). Consistently, STAT-3 DNA-binding activity as assessed by the
electrophoretic mobility shift assay was abnormally sustained in these cells compared to H69
cells unless the CCLP1 cells were DAC-treated (Figure 6C). Thus, we could reproduce our
findings in MzChA-1 cells of SOCS-3 silencing by methylation in an additional human
cholangiocarcinoma cell line.
Does restoration of SOCS-3 expression sensitize Mz-ChA-1 cells to TRAIL-mediated
apoptosis?
Cholangiocacinoma cells are resistant to TRAIL cytotoxicity, in part, due to enhanced STAT-3
dependent Mcl-1 expression.18 Therefore, we determined whether SOCS-3 restoration, which
should inhibit STAT-3 transduced expression of Mcl-1, sensitizes cholangiocarcinoma cells
to TRAIL cytotoxicity. Initially, we assessed the effect of SOCS-3 expression on expression
of proteins modulating TRAIL-mediated apoptosis. DAC-mediated restoration of SOCS-3
strongly reduced expression of Mcl-1 and, more modestly Bcl-XL, while expression of the anti-
apoptotic proteins survivin, cIAP-1 and -2 were unaffected (Figure 7A). Bcl-2 was undetectable
in this cell line using immunoblot analysis, consistent with our previous study (data was not
shown).20 Similarly, suppression of SOCS-3 expression in H69 cells by siRNA increased
Mcl-1 expression, modestly increased Bcl-XL, and had no effect on survivin, cIAP-1 or -2.
DAC treatment alone induced modest apoptosis in Mz-ChA-1 cells (Figure 7B and 7C).
However, incubation with DAC markedly enhanced TRAIL-mediated apoptosis despite
simultaneous IL-6 administration (Figure 7B and 7C). The enhanced cell death of DAC-treated
cells was not due to alterations in protein levels of the death-inducing signaling complex
(DISC) including TRAIL-R1, –R2, caspase 8 and FADD42 (not shown). TRAIL expression
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in the cholangiocarcinoma cells was not detected by immunoblotting of cell lysates nor by
examining the culture media for TRAIL secretion by an ELISA assay. Finally, the enhanced
death could be directly attributed to SOCS-3 expression as forced expression of SOCS-3
reduced Mcl-1 protein expression but not that of the other anti-apoptotic proteins (Figure 8A),
and enhanced TRAIL cytotoxicity (Figure 8B and 8C). These results indicate that increased
SOCS-3 expression, either by demethylation or transfection, reduces cellular Mcl-1 levels and
sensitizes the cells to TRAIL-mediated cytotoxicity.
DISCUSSION
The principal findings of this study relate to the mechanisms and biological consequences of
IL-6-mediated sustained STAT-3 activation in cholangiocarcinoma tissue and cells. The results
of the present study demonstrate that: a) there is an inverse relationship between STAT-3
phosphorylation and SOCS-3 expression; b) SOCS-3 silencing is attributable to transcriptional
inactivation via CpG island methylation of the socs-3 promoter; and c) reconstitution of
SOCS-3 expression reduces the duration and magnitude of IL-6-mediated STAT-3
phosphorylation, decreases cellular Mcl-1 levels, and sensitizes cholangiocarcinoma cells to
TRAIL-induced killing. Epigenetic therapy to re-express SOCS-3 may be useful in the therapy
of human cholangiocarcinoma.
IL-6 is a pivotal growth and survival factor in human cholangiocarcinoma14–16 and signals,
in part, through the JAK1/STAT-3 pathway.18 Normally, this pathway induces expression of
SOCS-3 which turns off IL-6 signaling through its recruitment to Tyr759 of gp130, where it
blocks JAK1 activation.23–25 Our study suggests this feed back loop is inactivated in a subset
of human cholangiocarcinomas. For example, immunohistochemical analysis demonstrated
constitutive nuclear Tyr705 phosphorylated STAT-3 in about 62% of human
cholangiocarcinoma specimens examined whereas SOCS-3 expression was very low (present
in less than a third of cells) in these cancers. We found no mutations when the socs-3 gene
from these cancers was sequenced, but rather extensive promoter CpG island methylation,
suggesting epigenetic silencing of this gene. Mechanistic evidence for epigenetic silencing was
obtained in both the Mz-ChA-1 and CCLP1 cell lines where the demethylating agent DAC
restored SOCS-3 expression and terminated the otherwise sustained Tyr705 phospho-STAT-3
response to IL-6 stimulation. Epigenetic silencing of SOCS-3, therefore, permits constitutive
IL-6/STAT-3 signaling in human cholangiocarcinoma allowing this cytokine to participate in
the genesis and progression of human cholangiocarcinoma. Along these lines, epigenetic
silencing of SOCS-3 has also been described in human lung cancer,30 head and neck cancers,
31 and hepatocellular cancer.32 Thus, epigenetic silencing of SOCS-3 is likely a critical
mechanism in cancer biology allowing the cancer to utilize the inflammatory cytokine as
survival and growth factor.
While human tumor samples manifested an inverse relationship between activated STAT-3
and SOCS-3 expression, the two cancer cell lines used did not demonstrate high levels of either
STAT-3 activation or SOCS-3 expression. This may reflect the environment of the tumor
(ongoing inflammation) versus the relatively quiescent conditions of cell culture. The
inflammatory environment of the tumor demands ongoing signaling (phospho-STAT-3) or
suppression of that signaling (SOCS-3 expression) due to the constant stimulation by cytokines.
The cell line is obviously not in an inflammatory environment, but upon stimulation with IL-6
does manifest the same signaling patterns as observed in the human cholangiocarcinoma
specimens. Therefore, the cell line appears to recapitulate the signaling events observed in the
human cancers as related to IL-6 signaling.
The mechanism for SOCS-3 CpG island promoter methylation was not examined in these
studies. Inflammation and, in particular IL-6 itself, has been associated with epigenetic
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silencing of genes through CpG island hypermethylation.43–45 For example, the promoter
region of p53 has been shown to be epigenetically modified by methyltransferases, resulting
in decreased levels of expression.46, 47 Multiple myeloma cells treated with IL-6 exhibit an
increase in the expression of the DNA maintenance methylation enzyme, DNMT-1 with
silencing of p53 expression.44 Therefore, it appears that IL-6 is capable of maintaining
promoter methylation thus representing one of the possible mechanisms used by inflammatory
mediators in the growth and survival of tumors. The mechanisms responsible for socs-3
promoter methylation will require further study, especially the potential role of inflammatory
cytokines such as IL-6.
Consistent with the molecular heterogeneity of human cancers, 16 of 26 examined human
cholangiocarcinoma specimens displayed constitutive STAT-3 activation and silencing of
SOCS-3 (present in less than 1 in 3 cells); three tumors manifested SOCS-3 expression and as
expected no Tyr705 phosphorylation of STAT-3. The remaining samples were intermediate
for both P-STAT-3 and SOCS-3. This does not exclude a role for IL-6 in the SOCS-3 positive
cancers, as this cytokine also signals by activation of the mitogen activated protein kinase
family including p38 and p42/44, and also by the phosphatidylinositol-3 kinase/Akt pathway.
25, 48, 49 These pathways have also been demonstrated to be important in human
cholangiocarcinoma, especially expression of the anti-apoptotic protein Mcl-1.19, 50, 51
Therefore, cholangiocarcinomas may use different IL-6 signaling pathways to achieve the same
phenotype, namely apoptosis resistance.
We have recently demonstrated that human cholangiocarcinomas paradoxically express the
death ligand TRAIL.52 Indeed, TRAIL promotes an invasive phenotype in these cancers.
Cholangiocarcinomas are resistant to TRAIL-mediated apoptosis due to enhanced expression
Mcl-1,20 and, therefore, Mcl-1 appears to be a master switch determining whether these
cancers live or die. IL-6/JAK1 mediated STAT-3 activation is one mechanism by which Mcl-1
is upregulated in these cancers.18 Indeed, we have recently demonstrated a STAT-3 response
element in the Mcl-1 human promoter.18 Consistent with these data, the demethylating agent
DAC, which restores SOCS-3 expression and inhibits IL-6 prolonged STAT-3 activation,
reduced Mcl-1 protein expression. The DAC reduction of Mcl-1 expression was associated
with sensitization to TRAIL-cytotoxicity. Although DAC has been shown to sensitize cells to
apoptosis by multiple mechanisms,34, 53–55 we did not observe a significant change in other
apoptosis modulators in our current study. While Bcl-XL, cIAP, and survivin can be regulated
by STAT-3 activation in some conditions, we do not find their expression dominantly tied to
STAT-3 signaling in cholangiocarcinoma cells. Presumably, the dominant regulation of their
expression in cholangiocarcinoma cells is via other transcription factors, but this was not
examined in the present study. Collectively, our current observations suggest SOCS-3 re-
expression can sensitize cholangiocarcinoma cells to TRAIL cytotoxicity by turning off IL-6/
STAT-3 signaling cascades resulting in Mcl-1 downregulation.
In conclusion, the present study demonstrates that IL-6-mediated sustained STAT-3 activation
in human cholangiocarcinoma is likely due to SOCS-3 epigenetic silencing via
hypermethylation of CpG islands within its promoter region. SOCS-3 re-expression by
demethylating agent or socs-3 gene transfer reduces STAT-3 activation and expression of its
target gene Mcl-1. This reduction in Mcl-1 sensitizes cholangiocarcinoma cells to TRAIL-
induced cytotoxicity. These findings highlight SOCS-3 as a pivotal negative regulator of the
IL-6/STAT-3 pathway and provide new perspectives for epigenetic therapy to restore SOCS-3
in this cancer. Indeed, as a variety of nucleoside and non-nucleoside DNA-methylation
inhibitors have been developed for cancer therapy,56, 57 the use of these agents in the treatment
of cholangiocarcinoma merits further study.
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Figure 1. (A) Inverse correlation between tyrosine705 phosphorylated STAT-3 (P-STAT-3) and
SOCS-3 expression in human cholangiocarcinoma (CCA) tissue
Immnohistochemistry for P-STAT-3 and SOCS-3 was performed using 26 surgically resected
human CCA specimens (400X magnification). The percent of cells with cytoplasmic SOCS-3
was assessed, as was the percent of cells with nuclear P-STAT-3 staining. Samples are shown
with positive P-STAT-3 (70–100% of cells) with low SOCS-3 staining (<30%), and separately
with negative P-STAT-3 (<30%) and high SOCS-3 staining (>70%). (B) Quantitative
analysis of SOCS-3 staining versus P-STAT-3 staining. Cells were examined and
quantitated for P-STAT-3 nuclear staining and SOCS-3 cytoplasmic staining. At least 500 cells
per specimen were counted. Each point represents the average value for one sample. Bars
represent the mean SOCS-3 staining for all specimens within each subset of P-STAT-3 staining.
(C) DNA methylation of the socs-3 promoter is associated with SOCS-3 silencing.
Genomic DNA was extracted from either SOCS-3 (+) or SOCS-3 ( ) CCA tissue procured by
laser capture microdissection (LCM). Bisulfite-modified DNA was subjected to methylation-
specific PCR as described in the Materials and Methods section using either a methylation-
(M) or unmethylation- (U) specific primer set for the socs-3 promoter. (D, E) CpG island
methylation of the socs-3 promoter is specific for CCA. Genomic DNA was extracted from
paired tumor and non-tumor tissue (uninvolved bile duct epithelial cells and hepatocytes)
procured by LCM. Cell-type specific genomic DNA was treated with bisulfite, subjected to
methylation-specific PCR of the socs-3 promoter region (D) and sequenced (E). A total of 44
CpG sites located between nucleotides -678 and -216 of the socs-3 promoter were sequenced
(E). The horizontal squares represent CpG islands while the vertical squares represent the
individual 5 clones sequenced. Each black square represents a methylated cytosine residue
within the CpG islands.
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Figure 2. (A) IL-6-mediated P-STAT-3 is sustained in the Mz-ChA-1 cholangiocarcinoma cells but
not in non-malignant H69 cells
Immunoblot analysis using anti-P-STAT-3 and anti-SOCS-3 antisera was performed using
whole cell lysates (25 g protein per lane) from the human cholangiocarcinoma cell line, Mz-
ChA-1, and an immortalized non-malignant human cholangiocyte cell line, H69 cells,
following treatment with IL-6 (10 ng/mL). Total cellular levels of STAT-3 and -actin were
also confirmed by immunoblot analysis. (B) IL-6 induces SOCS-3 mRNA expression in H69
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cells but not in Mz-ChA-1 cells. At various time points after expose to IL-6 (10 ng/mL), total
cellular RNA was isolated from the H69 and Mz-ChA-1 cells. SOCS-3 mRNA expression was
quantitated by real-time PCR as described in the Materials and Methods section. The relative
expression of SOCS-3 mRNA was expressed as a ratio of SOCS-3/18S rRNA (internal control)
copies/ L (n=4). *, p<0.05, versus H69 cells prior to IL-6 exposure.
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Figure 3. CpG island methylation within the socs-3 promoter is observed in Mz-ChA-1 but not H69
cells
Genomic DNA extracted from the cell lines was treated with bisulfite and then subjected to
methylation-specific PCR (A) using the methylated DNA- (M) and unmethylated DNA- (U)
specific primer sets. PCR products were sequenced for the 44 CpG sites located between
nucleotides -678 and -216 of the socs-3 promoter as described in the Materials and
Methods section (B). The horizontal squares represent CpG islands while the vertical squares
represent the individual 5 clones sequenced. Each black square represents a methylated
cytosine residue within the CpG islands.
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Figure 4. (A) 5-aza-2 -deoxycytidine (DAC) treatment restores IL-6-mediated SOCS-3 protein
expression in Mz-ChA-1 cells
Mz-ChA-1 cells were incubated in the absence or presence of DAC (1 or 5 M) for 96 hr,
followed by treatment with 0.5 M trichostatin A (TSA) or vehicle for additional 24 hr.
Thereafter, the cells were stimulated with IL-6 (10 ng/mL) for 1hr. Immunoblot analysis using
anti-P-STAT-3 and anti-SOCS-3 antisera was performed using whole cell lysates (25 g
protein per lane). Total cellular levels of STAT-3 and -actin were also confirmed by
immunoblot analysis. (B) DAC treatment restores IL-6-mediated SOCS-3 mRNA
expression in Mz-ChA-1 cells. Mz-ChA-1 cells were incubated in the absence or presence of
DAC (1 or 5 M) for 96 hr, followed by treatment with trichostatin A (TSA) as indicated or
vehicle for additional 24 hr. Then, the cells were incubated in the presence of 10 ng/mL of IL-6
for 1hr. Total cellular RNA was isolated. The relative SOCS-3 mRNA expression was
quantitated by real-time PCR (n=4). *, p<0.01, **, p<0.05, versus cells treated with
vehicle; #, p<0.01 for cells treated with 1 M DAC with and without TSA; ##, p<0.01 for cells
treated with 1 M DAC alone. (C) DNA methylation of the socs-3 promoter in Mz-ChA-1
cells is reversible by DAC treatment. After treatment with DAC (1 or 5 M) or vehicle,
genomic DNA was extracted from the Mz-ChA-1 cells, treated with bisulfite and subjected to
methylation specific PCR using the methylated DNA- (M) and unmethylated DNA- (U)
specific primer sets.
Isomoto et al. Page 21

















































Isomoto et al. Page 22

















































Figure 5. (A) DAC treatment attenuates the prolonged tyrosine705 STAT-3 phosphorylation in
response to IL-6
Mz-ChA-1 cells were treated with DAC (5 M) for 96 hr, followed by stimulation with IL-6
(10 ng/mL). Whole cell lysates (25 g per lane) were prepared at various time points after
exposure to the cytokine and were subjected to immunoblot analysis using anti-P-STAT-3, -
SOCS-3, -STAT-3 and - -actin antisera. (B) Enforced expression of SOCS-3 by socs-3 gene
transfection results in rapid termination of the phospho-STAT-3 response upon IL-6
stimulation of Mz-ChA-1 cells. Cells were transfected with pcDNA3-hSOCS-3 or empty
vector as described in the Materials and Methods section. The cells were incubated in the
presence of IL-6 (10 ng/mL) for 1 to 12 hr. Immunoblot analysis using anti-P-STAT-3 and
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anti-SOCS-3 antisera was performed using whole cell lysates (25 g per lane). Total cellular
levels of STAT-3 and -actin were also confirmed by immunoblot analysis. (C) siRNA
targeted silencing of SOCS-3 in H69 cells enhances tyrosine705 STAT-3
phosphorylation. H69 cells were transfected with siRNA complementary to the SOCS-3 gene
or control small RNA. 48 hr after transfection, cells were incubated with IL-6 (10 ng/mL) for
2hr, whole cell lysates (25 g per lane) were subjected to immunoblot analysis
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Figure 6. (A) The SOCS-3 promoter is methylated in CCLP cells
Similar to Mz-ChA-1 cells, the SOCS-3 promoter is methylated in CCLP cells, reversible by
DAC-treatment (5 M). (B) DAC restores IL-6-induced SOCS-3 expression in CCLP
cells. CCLP cells were untreated or pretreated with 5 M DAC for 96 hours followed by IL-6
treatment for 0, 1, or 6 hours. IL-6 did not induce SOCS-3 unless the demethylating agent was
used. (C) IL-6 triggers sustained STAT-3 activation in CCLP cells while H69 cells or
DAC-treated CCLP cells manifest transient STAT-3 activation. Electorphoretic mobility
shift assay demonstrates the expected transient STAT-3 activation in H69 cells upon IL-6
treatment (peak at 1 hour). CCLP cells, on the other hand, show sustained STAT-3 activation.
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Pretreatment for 96 hours with DAC (5 M) restored the transient activation (peak at 2 hours).
Note the kinetics are slightly different between H69 cells and DAC-treated CCLP cells
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Figure 7. (A) SOCS-3 expression affects Mcl-1 expression
Ninety-six hours after treatment with 5 M DAC or vehicle, Mz-ChA-1 cells were stimulated
with IL-6 (10 ng/mL) for 2 hours. Separately, Mz-ChA-1 cells were transfected with anti-
SOCS-3 siRNA for 48 hours, followed by 2 hours of IL-6 treatment. Immunoblot analysis
using anti-Mcl-1, -Bcl-XL, -survivin, -C-IAP-1 and -2 and – -actin antisera was performed
using whole cell lysates (25 g per lane). (B, C) SOCS-3 expression by DAC treatment
sensitizes Mz-ChA-1 cells to TRAIL-mediated apoptosis. After 96-hr-treatment with DAC
(5 M) or vehicle, Mz-ChA-1 cells were treated with TRAIL (2 ng/mL) (+) or vehicle ( ) in
the presence of 10% serum or IL-6 (10 ng/mL) for 12 hr. Apoptosis was quantitated
morphologically with DAPI staining under fluorescence microscopy (B) or biochemically by
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measuring caspase 3/7 activity (C). Data were expressed as percentages of apoptotic cells (B)
or relative fluorescence unit (RFU) of caspase 3/7 activity (C) from 3 separate experiments. *,
p<0.05, **, p<0.01 versus control group (cells without any treatment incubated either with
10% serum condition or IL-6); #, p<0.01 for cells treated with either DAC or TRAIL alone.
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Figure 8. (A) Enforced SOCS-3 expression reduces tyrosine705 phosphorylated STAT-3 and Mcl-1
in Mz-ChA-1 cells
Following transfection with pcDNA3-hSOCS-3 or empty vector, Mz-ChA-1 cells were
incubated with IL-6 (10 ng/mL) for 2 hr. Whole cell lysates (25 g per lane) were prepared
and subjected to immunoblot analysis using anti-P-STAT-3, -SOCS-3, -Mcl-1, -Bcl-XL, -
survivin and -C-IAP-1 and -2 antisera. (B, C) Enforced SOCS-3 expression sensitizes Mz-
ChA-1 cells to TRAIL-mediated apoptosis. Mz-ChA-1 cells transfected with pcDNA3-
hSOCS-3 or empty vector were incubated in the absence ( ) or presence (+) of TRAIL for 12
hr. Apoptosis was quantitated morphologically with DAPI staining under fluorescence
microscopy (B) or biochemically by measuring caspase 3/7 activity (C). Data were expressed
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as percentages of apoptotic cells (B) or RFU of caspase 3/7 activity (C) from 3 separate
experiments. *, p<0.05, **, p<0.01 for cells transfected with empty vector without TRAIL
treatment, #, p<0.01 for TRAIL-treated cells transfected with empty vector or cells transfected
with pcDNA3-hSOCS-3 without TRAIL treatment.
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Table 1
Sequences for primers employed in this study
Primer pair Annealing temperature (cycle) Product size
socs-3 gene sequence
5 -UTR to exon
1
F: 5 -TGCAGAGTAGTGACTAAACATTACAAGAA-3 58°C (35) 235
R: 5 -GGAGGGGACCAGGAGAGG-3
exon 1 to intron F: 5 -CGACTTGGACTCCCTGCT-3 56°C (35) 392
R: 5 -GAGGGGAAACCGGGAAAAG-3
intron to exon 2 F: 5 -CTCAGTCCCGGGAGCTTTTC-3 58°C (35) 715
R: 5 -GCTGGTACTCGCTGTTGGAG-3
exon 2 F: 5 -GGTCACCCACAGCAAGTTT-3 55°C (35) 676
R: 5 -TTAAAGCGGGGCATCGTACT-3
exon 2 to 3 -
UTR
F: 5 -AGTACGATGCCCCGCTTT-3 55°C (35) 670
R: 5 -GCACCAGGTAGACTTTGGAAC-3
3 -UTR F: 5 -CCTGGTGACATGCTCCTCT-3 55°C (35) 629
R: 5 -CAGGTAATTCCATCGCTGCT-3
3 -UTR F: 5 -TCATTGGAGAGGCTGGACTG-3 55°C (35) 400
R: 5 -GCAAAGTTTGACTTGGATTGG-3
Methylation specific PCR
Methylated F: 5 -GGAGATTTTAGGTTTTCGGAATATTTC-3 58°C (35) 142
R: 5 -CCCCCGAAACTACCTAAACGCCG-3








F: 5 -TTCTACTGGAGCGCAGTGAC-3 60°C (40) 127
R: 5 -ACTGGGTCTTGACGCTGAG-3
UTR, untranslated region; F, forward; R, reverse; socs-3, suppressor of cytokine signaling 3
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